Publications by authors named "Daniel Checketts"

Claim this Profile
L
Long-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program.
Arie Weinstock, E Martina Bebin, Daniel Checketts, Gary D Clark, Jerzy P Szaflarski

Epilepsia Open· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis.
Francois A Bethoux, Rachel Farrell, Daniel Checketts, Natasha Sahr, Joris Berwaerts

Mult Scler Relat Disord· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of nabiximols oromucosal spray on spasticity in people with multiple sclerosis: Treatment effects on Spasticity Numeric Rating Scale, muscle spasm count, and spastic muscle tone in two randomized clinical trials.
Jacqueline Nicholas, Fred Lublin, Sylvia Klineova, Joris Berwaerts, Robert Chinnapongse, Daniel Checketts

Mult Scler Relat Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term efficacy and safety of cannabidiol in patients with treatment-resistant epilepsies: Four-year results from the expanded access program.
Jerzy P Szaflarski, Orrin Devinsky, Merrick Lopez, Yong D Park, Pilar Pichon Zentil, Daniel Checketts

Epilepsia· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to onset of cannabidiol treatment effect and resolution of adverse events in tuberous sclerosis complex: Post hoc analysis of randomized controlled phase 3 trial GWPCARE6.
Joyce Y Wu, Hannah R Cock, Orrin Devinsky, Charuta Joshi, Ian Miller, Daniel Checketts

Epilepsia· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on cannabidiol in patients with Dravet syndrome: Results of a long-term open-label extension trial.
Ingrid E Scheffer, Jonathan J Halford, Ian Miller, Rima Nabbout, Rocio Sanchez-Carpintero, Daniel Checketts

Epilepsia· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials.
Jennifer Madan Cohen, Daniel Checketts, Eduardo Dunayevich, Boudewijn Gunning, Ann Hyslop

Epilepsia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial.
Anup D Patel, Maria Mazurkiewicz-Bełdzińska, Richard F Chin, Antonio Gil-Nagel, Boudewijn Gunning, Daniel Checketts

Epilepsia· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
Michael Privitera, Hari Bhathal, Matthew Wong, J Helen Cross, Elaine Wirrell, Daniel Checketts

Epilepsia· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma.
Chris Twelves, Michael Sabel, Daniel Checketts, Sharon Miller, Bola Tayo

Br J Cancer· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Elizabeth A Thiele, E Martina Bebin, Hari Bhathal, Floor E Jansen, Katarzyna Kotulska, Daniel Checketts

JAMA Neurol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Boudewijn Gunning, Maria Mazurkiewicz-Bełdzińska, Richard F M Chin, Hari Bhathal, Charlotte Nortvedt, Daniel Checketts

Acta Neurol Scand· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabidiol efficacy independent of clobazam: Meta-analysis of four randomized controlled trials.
Orrin Devinsky, Elizabeth A Thiele, Stephen Wright, Daniel Checketts, Gilmour Morrison

Acta Neurol Scand· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of nabiximols cannabinoid medicine for paediatric spasticity in cerebral palsy or traumatic brain injury: a randomized controlled trial.
Charlie Fairhurst, Ram Kumar, Daniel Checketts, Bola Tayo, Susie Turner

Dev Med Child Neurol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Ian Miller, Ingrid E Scheffer, Boudewijn Gunning, Rocio Sanchez-Carpintero, Antonio Gil-Nagel, Daniel Checketts

JAMA Neurol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abrupt withdrawal of cannabidiol (CBD): A randomized trial.
Lesley Taylor, Julie Crockett, Bola Tayo, Daniel Checketts, Kenneth Sommerville

Epilepsy Behav· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Linda C Laux, E Martina Bebin, Daniel Checketts, Michael Chez, Robert Flamini

Epilepsy Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabidiol in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
Elizabeth Thiele, Eric Marsh, Maria Mazurkiewicz-Beldzinska, Jonathan J Halford, Boudewijn Gunning, Daniel Checketts

Epilepsia· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Jerzy P Szaflarski, Elizabeth Martina Bebin, Anne M Comi, Anup D Patel, Charuta Joshi, Daniel Checketts

Epilepsia· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Orrin Devinsky, Anup D Patel, J Helen Cross, Vicente Villanueva, Elaine C Wirrell, Daniel Checketts

N Engl J Med· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation and calibration of a binocular infrared pupillometer for measuring relative afferent pupillary defect.
Audrey Shwe-Tin, Guy T Smith, Daniel Checketts, Ian E Murdoch, Daniel Taylor

J Neuroophthalmol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis